06 SEP 2002

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/48 — A1

(11) International Publication Number: WO 99/39699

(43) International Publication Date: 12 August 1999 (12.08.99)

(21) International Application Number: PCT/US98/02265

(22) International Filing Date: 9 February 1998 (09.02.98)

(71) Applicant: RTP PHARMA, INC. [US/CA]; 810, chemin du Golf, Ile des Soeurs, Quebec H3E 1A8 (CA).

(72) Inventors: BOLONICK, Joel; Apartment 12, 2435 College Avenue, Berkeley, CA 94704 (US). STEWART, Alan; 6840 Paso Robles Drive, Oakland, CA 94611 (US).

(74) Agent: CRAWFORD, Arthur, R.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: TREATMENT OF CHRONIC INFLAMMATORY DISORDERS OF THE GASTROINTESTINAL TRACT

(57) Abstract

The present disclosure relates to an oral formulation for treating gastrointestinal inflammation that includes an effective amount of budesonide suspended in an edible oil, typically a vegetable oil. A method for treating gastrointestinal inflammation in mammals is also described and includes orally administering a composition of this invention to a mammal. In one embodiment, an initial dosage is administered daily for about two to four weeks and the dosage is subsequently tapered, generally at about two week intervals, in response to a reduction in symptoms until a minimum dose that controls symptoms is achieved.



162162



G00002